Lincoln Pharmaceuticals Ltd.

NSE: LINCOLN BSE: 531633 SECTOR: Pharmaceuticals & Drugs  34k   282   36

378.85
-2.45 (-0.64%)
NSE: Today, 10:34 AM

Price Summary

Today's High

₹ 384.7

Today's Low

₹ 377.35

52 Week High

₹ 456.3

52 Week Low

₹ 270

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

758.83 Cr.

Enterprise Value

742.44 Cr.

No. of Shares

2 Cr.

P/E

10.41

P/B

1.51

Face Value

₹ 10

Div. Yield

0.39 %

Book Value (TTM)

₹  250.86

CASH

18.43 Cr.

DEBT

2.04 Cr.

Promoter Holding

47 %

EPS (TTM)

₹  36.4

Sales Growth

11.63%

ROE

17.35 %

ROCE

24.29%

Profit Growth

11.41 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year11.63%
3 Year10.17%
5 Year9.18%

Profit Growth

1 Year11.41%
3 Year14.14%
5 Year20.41%

ROE%

1 Year17.35%
3 Year17.8%
5 Year17.75%

ROCE %

1 Year24.29%
3 Year23.77%
5 Year22.26%

Debt/Equity

0.0047

Price to Cash Flow

9.96

Interest Cover Ratio

67.1169618857261

CFO/PAT (5 Yr. Avg.)

1.1078908640667

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2023 47 0
Dec 2022 46.34 0
Sep 2022 44.08 0
Jun 2022 44.08 0
Mar 2022 42.05 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROCE of 23.7710982645739% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 67.1169618857261.
  • Company’s PEG ratio is 0.912012431305382.
  • The company has an efficient Cash Conversion Cycle of -10.2631787638367 days.
  • Company has a healthy liquidity position with current ratio of 3.37463031243409.
  • The company has a good cash flow management; CFO/PAT stands at 1.1078908640667.

 Limitations

  • The company has shown a poor revenue growth of 10.1698033653183% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
Net Sales 102.54 123.47 140.61 133.77 112.46
Total Expenditure 85.11 106.56 111.7 107.01 95.86
Operating Profit 17.44 16.91 28.91 26.75 16.6
Other Income 1.89 6.5 5.69 6.36 3.95
Interest 0.57 0.41 0.14 0.33 1.15
Depreciation 2 2.07 2.42 2.26 2.41
Exceptional Items 0 0 0 0 0
Profit Before Tax 16.76 20.93 32.03 30.52 16.98
Tax 5.74 5.91 8.32 8.9 4.42
Profit After Tax 11.02 15.01 23.71 21.61 12.56
Adjusted EPS (Rs) 5.5 7.49 11.84 10.79 6.27

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 324.95 353.04 376.09 422.91 472.08
Total Expenditure 279 292.71 316.72 335.87 376.61
Operating Profit 45.96 60.33 59.37 87.04 95.47
Other Income 5.8 6.58 12.13 5.74 10
Interest 4.26 3.84 1.98 1.55 1.45
Depreciation 4.4 4.92 5.47 7.56 8.09
Exceptional Items 0 0 0 0 0
Profit Before Tax 43.1 58.14 64.05 83.67 95.93
Tax 10.34 11.51 14.48 21.42 26.57
Net Profit 32.76 46.64 49.56 62.25 69.36
Adjusted EPS (Rs.) 16.38 23.32 24.78 31.08 34.63

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 20 20 20 20.03 20.03
Total Reserves 199.54 242.6 284.49 346.36 412.85
Borrowings 6.13 1.69 0.52 0.14 0
Other N/C liabilities 16.76 23.22 37.47 40.73 10.99
Current liabilities 98.8 90.02 69.44 93.45 110.46
Total Liabilities 341.24 377.54 411.92 500.72 554.34
Assets
Net Block 82.95 88.45 91.03 110.64 131.88
Capital WIP 0.29 1.94 0.04 1.69 16.05
Intangible WIP 0 0 0 0 0
Investments 27.74 27.74 25.79 0.05 0.05
Loans & Advances 31.63 50.27 65.69 61.57 31.83
Other N/C Assets 0.34 0.33 0.03 0.45 1.75
Current Assets 198.29 208.81 229.35 326.31 372.78
Total Assets 341.24 377.54 411.92 500.72 554.34
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 43.1 58.14 64.05 83.67 95.93
Adjustment 7.95 6.53 5.38 4.75 1.49
Changes in Assets & Liabilities -21.03 3.01 15.27 0.42 2.4
Tax Paid -8.69 -16.63 -13.98 -19.45 -23.64
Operating Cash Flow 21.33 51.06 70.71 69.39 76.18
Investing Cash Flow -13.64 -22.32 -28.99 -64.39 -78.08
Financing Cash Flow -4.17 -29.88 -38.1 -5.74 -2.56
Net Cash Flow 3.51 -1.14 3.61 -0.74 -4.46

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Promoters 42.05 44.08 44.08 46.34 47.00
munjal mahendrabha... 3.08 3.08 3.08 3.08 3.08
ashish rajanibhai ... - - - - -
aashish rajanibhai... 2.65 2.65 2.65 2.65 2.65
mansi munjal patel 4.00 4.00 4.00 4.00 4.00
rajnibhai gulabdas... 1.53 1.53 1.53 1.53 1.53
mahendrabhai gulab... 1.51 - 1.51 1.51 1.51
sunmed corporation... 2.50 2.50 2.50 2.50 2.50
kailashben mahendr... 0.65 0.40 0.40 0.65 0.65
downtown travels l... 2.38 2.38 2.38 2.38 2.38
patel siddharth ra... 2.10 - 2.10 2.10 2.10
patel siddharth ra... - 2.10 - - -
hashmukhbhai ishwa... 1.87 1.87 1.87 1.87 1.87
mahendra gulabdas ... - 1.51 - - -
kalpanaben rajnibh... 1.47 1.47 1.47 1.47 1.47
anand arvinbhai pa... 0.66 0.66 0.66 0.66 0.66
shardaben gulabdas... 0.16 1.16 0.16 0.16 0.16
shivani b. shah 1.01 1.01 1.01 1.01 1.01
patel nishitkumar ... 0.91 0.91 0.91 0.91 0.91
hansaben arvindbha... 0.59 0.59 0.59 0.59 0.59
renukaben maheshbh... 0.87 0.87 0.87 0.87 0.87
dharmisthaben bhag... 0.63 0.63 0.63 0.63 0.63
arvindbhai gulabda... 0.56 0.56 0.56 0.56 0.56
downtown finance p... 0.53 0.53 0.53 0.53 0.53
manguben i patel 0.46 0.46 0.46 0.46 0.46
mihirbhai vithalbh... 0.44 - 0.44 0.44 0.44
mihir viththalbhai... - 0.44 - - -
jigar hasmukhbhai ... 0.26 0.26 0.26 0.26 0.26
patel aniruddh has... 0.26 0.26 0.26 0.26 0.26
dharmistaben hashm... 0.33 - 0.33 0.33 0.33
yogeshkumar ishwer... 0.04 0.33 0.04 0.04 0.04
dharmistaben hasmu... - 0.33 - - -
amar arvindbhai pa... 0.30 0.30 0.30 0.30 0.30
nidhi mahendrabhai... 0.27 0.27 0.27 0.27 0.27
ishwarbhai ambalal... 0.25 0.25 0.25 0.25 0.25
bhagirathbhai trib... 0.11 0.11 0.11 0.11 0.11
karnavati distribu... 0.05 0.05 0.05 0.05 0.05
PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Investors 57.95 55.92 55.92 53.66 53.00
digital biotech pv... 7.00 7.00 7.00 7.00 7.00
bonanza portfolio ... - 1.13 1.57 3.11 -
paru securities pv... - - - 1.30 -
kishor m. shah 2.39 2.39 2.39 2.39 2.39
piyush jitendrabha... - - - - -
piyush jitendrabha... 2.19 2.19 2.19 2.19 2.19
kamlesh jayantilal... 2.07 2.06 2.06 2.07 2.07
hareshbhai ambalal... 2.07 2.07 2.07 2.07 2.07
sonali sanjay amin 2.06 2.06 2.06 2.06 2.06
sanjay gijubhai am... 2.06 2.06 2.06 2.06 2.06
kaushal natubhai p... 2.06 2.06 2.06 2.06 2.06
bharatbhai babulal... - 2.06 2.06 - -
sonali sanjaykumar... - - - - -
sharad kanayalal s... 1.50 1.50 1.50 1.50 1.50
bonanza portfolio ... 1.45 - - - -
standard greases &... - - - - -
janus consolidated... - - - 1.01 -
vraj dyes & drugs ... 1.09 1.09 1.09 1.09 1.09
iepf 0.14 - - 0.09 0.09

Annual Reports

Ratings & Research Reports

Company Presentations

  • PresentationQ3FY21 24 May 2021
  • PresentationQ1FY21 23 Dec 2020
  • PresentationQ2FY21 23 Dec 2020
  • Presentation Q3FY20 19 May 2020

Company News

Lincoln Pharmaceuticals informs about press release26 May 2023, 1:13PM Lincoln Pharmaceuticals informs about outcome of board meeting25 May 2023, 3:09PM Lincoln Pharma - Quaterly Results25 May 2023, 11:42AM Lincoln Pharma - Quaterly Results25 May 2023, 11:42AM Lincoln Pharma - Quaterly Results25 May 2023, 11:42AM Lincoln Pharmaceuticals informs about issuance of duplicate share certificate12 May 2023, 4:55PM Lincoln Pharmaceuticals informs about revised disclosures 4 May 2023, 12:59PM Lincoln Pharma - Quaterly Results9 Feb 2023, 12:51PM Lincoln Pharma - Quaterly Results9 Feb 2023, 12:51PM Lincoln Pharma - Quaterly Results9 Feb 2023, 12:51PM Lincoln Pharmaceuticals informs about disclosure 16 Dec 2022, 4:00PM Lincoln Pharmaceuticals informs about disclosure 7 Dec 2022, 4:38PM Lincoln Pharmaceuticals informs about disclosure 3 Dec 2022, 3:34PM Lincoln Pharmaceuticals informs about disclosure 30 Nov 2022, 5:09PM Lincoln Pharmaceuticals informs about disclosure of related party transactions24 Nov 2022, 5:07PM Lincoln Pharmaceuticals informs about outcome of board meeting 10 Nov 2022, 5:10PM Lincoln Pharma - Quaterly Results10 Nov 2022, 11:28AM Lincoln Pharma - Quaterly Results10 Nov 2022, 11:28AM Lincoln Pharmaceuticals informs about outcome of board meeting9 Aug 2022, 3:01PM Lincoln Pharma - Quaterly Results9 Aug 2022, 1:29PM Lincoln Pharma - Quaterly Results9 Aug 2022, 1:29PM Lincoln Pharma - Quaterly Results9 Aug 2022, 1:29PM Lincoln Pharmaceuticals informs about disclosure7 Jun 2022, 4:55PM Lincoln Pharmaceuticals informs about audited financial results19 May 2022, 3:05PM Lincoln Pharma - Quaterly Results19 May 2022, 1:10PM Lincoln Pharma - Quaterly Results19 May 2022, 1:10PM Lincoln Pharma - Quaterly Results19 May 2022, 1:10PM Lincoln Pharma - Quaterly Results10 Feb 2022, 1:02PM Lincoln Pharma - Quaterly Results10 Feb 2022, 1:02PM Lincoln Pharma - Quaterly Results10 Feb 2022, 1:02PM Lincoln Pharmaceuticals informs about disclosure2 Dec 2021, 4:11PM Lincoln Pharmaceuticals informs about disclosure29 Nov 2021, 9:38AM Lincoln Pharmaceuticals informs about newspaper advertisement 12 Nov 2021, 4:16PM Lincoln Pharmaceuticals informs about updates20 Oct 2021, 2:30PM Lincoln Pharmaceuticals informs about AGM minutes20 Oct 2021, 2:15PM Lincoln Pharmaceuticals gets nod for all three departments Tablet, Capsule, Cream & Ointment8 Oct 2021, 3:16PM Lincoln Pharmaceuticals planning to launch Cephalosporin products21 Sep 2021, 12:19PM Lincoln Pharmaceuticals informs about press release16 Sep 2021, 12:09PM Lincoln Pharmaceuticals informs about 27th AGM7 Sep 2021, 12:41PM Lincoln Pharmaceuticals informs about disclosure16 Aug 2021, 5:28PM Lincoln Pharmaceuticals informs about disclosure28 Jun 2021, 4:50PM Lincoln Pharmaceuticals to hold board meeting17 May 2021, 5:37PM Lincoln Pharmaceuticals informs about clarification30 Apr 2021, 1:20PM Lincoln Pharmaceuticals launches Vitamin C plus Zinc Tablets30 Jul 2020, 12:22PM Lincoln Pharmaceuticals gets European Union GMP's nod for Khatraj facility19 May 2020, 2:26PM Lincoln Pharmaceuticals gets nod to manufacture HCQ to fight COVID 1927 Apr 2020, 12:42PM

Lincoln Pharma Stock Price Analysis and Quick Research Report. Is Lincoln Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Lincoln Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 76.1831 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Lincoln Pharma has a Debt to Equity ratio of 0.0047 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Lincoln Pharma , the EPS growth was 11.4135313669403 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Lincoln Pharma has OPM of 20.2233355483585 % which is a good sign for profitability.
     
  • ROE: Lincoln Pharma have a average ROE of 17.3545904023898 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Lincoln Pharma

X